Antiretroviral drugs for AIDS. (Q41116397)

27 September 2017

1 reference

title

Antiretroviral drugs for AIDS. (English)

1 reference

27 September 2017

J J Lipsky

1 reference

27 September 2017

language of work or name

English

0 references

publication date

1 September 1996

1 reference

27 September 2017

1 reference

27 September 2017

volume

348

1 reference

27 September 2017

issue

9030

1 reference

27 September 2017

page(s)

800-803

1 reference

Viral dynamics of HIV: implications for drug development and therapeutic strategies

27 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

Therapy for human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

Survival from early, intermediate, and late stages of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

Viral dynamics in human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

Viral counts count in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

Basic concepts in RNA virus evolution

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

Antiretroviral therapy for adult HIV-infected patients. Recommendations from a state-of-the-art conference. National Institute of Allergy and Infectious Diseases State-of-the-Art Panel on Anti-Retroviral Therapy for Adult HIV-Infected Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

Protease inhibitors for HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

Time to hit HIV, early and hard.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

Zidovudine use to reduce perinatal HIV type 1 transmission in an urban medical center

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

Viral gene products and replication of the human immunodeficiency type 1 virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

Safety and activity of saquinavir in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group P

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. ACTG 199 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

Relationship between plasma concentrations of 3'-deoxy-3'-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

HIV suppression by interleukin-16.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

A second coreceptor for HIV in early stages of infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2912333-4

7 January 2021

10.1016/S0140-6736(95)12333-4

Identifiers

DOI

1 reference

27 September 2017

1 reference